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Summary Ninety-seven cases of chronic myelomonocytic leukaemia (CMML) were examined retrospectively
for survival and possible prognostic factors including age, total white cell count, peripheral blood and bone
marrow monocyte counts, % double esterase (DE) positive cells in bone marrow and serum lysozyme. Age,
absolute monocyte counts and serum lysozyme proved to be significant independent prognostic indicators but
Cox model analyses showed serum lysozyme to be the most important factor whether taken as a continuous
or discrete (two groups) variable. Twelve cases of second malignancy were found, including 2 cases of
multiple myeloma, but this was not significantly greater than expected when compared with an age and sex
matched group.
Although cases with features of CMML have been identified Survival data was collected by examination of case notes
for many years and referred to under a variety of terms by one of the authors (ANS), and from the Yorkshire
(Broun, 1969; Linman, 1970; Saarni & Linman, 1971; Regional Cancer Registry. The immediate cause of death
Miescher & Farquet, 1974; Sexauer et al., 1974; Geary et al., (where applicable) was taken from the death certificate or
1975), it was only with the adoption of a fixed set of post-mortem report and survivals calculated from initial
diagnostic criteria (Bennett et al., 1982) that comparisons diagnosis.
could be made between studies by different centres. Chronic In total 97 cases were studied; 48 males and 49 females
myelomonocytic leukaemia (CMML) is now widely classified (male/female ratio 1:1) and complete survival and follow up
with the myelodysplastic syndromes (MDS) and charac- data were available in 79 cases.
terised haematologically by the presence of increased and
often atypical monocytes in the peripheral blood, together Morphological, cytochemical and serum lysozyme
with evidence of bone marrow dysplasia in any or all of the investigations
cell lines. CMML may however be viewed as a spectrum of
diseases with wide variations in peripheral blood leucocyte Morphology was examined on May-Grunwald-Giemsa
counts and clinical course and someinvestigatorstained peripheral blood and bone marrow smears and the CMML shoud
clin l considered as a distinct entity, with diagnosis of CMML made according to FAB criteria CMML should be (Bennett et al., 1982). Minimal diagnostic criteria for features of both myeloproliferative and myelodysplastic CMML were the presence of a total peripheral blood
disorders (Solal-Celigny et al., 1984; Milner etal., 1977). monocyte t of a totherwih ood Seea stde (Soa-Cein et al 194 Groupe monocyte count of >1 x 109 1-1, together with other
F ranastdiesCytogenetique ematl , 1986) havupe evidence of dysplasia in the peripheral blood or bone
examnecinic fytgeare oft C Lpatien i986ahate marrow, without any clinical history to suggest a secondary
to identify prognostic factors. Although reduced survival was cause for the monocytosis. The monocyte count was based to identify prognostic factors. Although reduced survival was on a standard coulter S-plus white cell plot, with a manual found to be associated with high white cell counts differential and adjusted to take account of nucleated red (Alessandrino et al., 1985), overall prognostic factors have cells. Any evidence of dysplasia (e.g. hypogranularity of
As most po e e e e myeloid cells, presence ofmicromegakaryocytes, and dysery-
numbersmo patins, wesexam e 9cases of CMmal thropoiesis) was noted and features such as haemoglobin numbers of patients, we examined 97 cases of CMML concentration, peripheral blood white cell and monocyte referred to this department for leukaemic diagnosis and counts and platelet count recorded. assessed various blood and bone marrow features as . . > . . ~~~~~~~~Cases of juvenile CGL were excluded from the study potential prognostic factors. Additionally, as it has been because although some features ofthis disease are similar to suggested that MDS may be associated with an increase in CMML, there is evidence to suggest that this condition second malignancies (Copplestone et al., 1986; Raz et al., should be considered as a separate diagnostic category 1984; Haznedar, 1985; Sans-Sabrafen et al., 1986; Mufti et (Altman et al., 1974; Thomas et al., 1981). al., 1983) data were collected about any other cancers The proportions of bone marrow cells showing double
present either before or after the diagnosis of CMML. (cx-naphthyl acetate and chloroacetate) esterase staining,
previously associated with MDS (Scott et al., 1983, 1984),
were cytochemically assessed by conventional techniques Matenials and methods (Yam et al., 1971).
Serum lysozyme was estimated as previously described
Patients studied (Milligan et al., 1984) by spectrophotometric measurement of
Cases examined were referred to this department for micrococcus lysodeikticus lysis; the normal range being 150-
diagnosis during the period 1981-1986. Blood and marrow 500uml-1 where 1 unit is defined as the amount of enzyme
specimens were taken at diagnosis into EDTA for causing a decrease in A450 of 0.001 min-t at 37°C.
morphological and cytochemical studies and a serum sample
was also taken in most cases for lysozyme estimation. Date Statistical analysis
of birth and age at diagnosis were noted as were details of Individual variables were examined for survival using the
survival and the presence of second malignancies, log-rank test (Peto et al., 1977) and also analysed separately
allowing for age as a stratified variable (grouped <75 yrs
Correspondence: C.S. Scott. and >75yrs).
Received 6 February 1987. Variables found to be significant or of borderline60 A.N. STARK et al.
significance at the 5% level were further investigated using 60
Cox's proportional hazards model (Cox, 1972) both as
continuous and discrete variables. Graphs of log (-log
(survival function)) for one variable stratified for another
were plotted to see whether there were any obvious 40
violations of the underlying assumption of proportional
hazard functions. There did not appear to be any evidence of
non-proportionality.
20
Results Co
During the period 1981-1986, 380 cases of MDS were 0
referred for diagnosis. These included refractory anaemia 2.5 4.5 6.5 8.5 >10
(RA; n=75), refractory anaemia with excess sideroblasts D9
(RAS; n=33), refractory anaemia with excess blasts and E 30Monocytecount(I- )
refractory anaemia with excess blasts in transformation Z
(RAEB & RAEBt; n=90), CMML (n=97) and MDS un-
classified (n =85). The latter group included patients in
which insufficient data was available to confidently diagnose 20
a particular MDS type but where a strong suspicion of MDS NR <500 u ml-'
was present (i.e. hypogranular neutrophils and giant platelets
on blood film, but only PB sample available for study). The 10
number of cases of CMML (97/380; 25%) is higher than
seen previously but it is likely that many patients with mild
refractory anaemia are not referred for diagnosis, thus hR
resulting in an apparent increase in the proportion of
CMML cases. In this respect it is notable that the number of 0 1000 2000 3000 4000 >5000
cases of RA seen (n=75; 20%) is lower than in other studies Serum lysozyme (500 uin-' intervals)
(Tricot et al., 1985).
Figure 1 Peripheral blood monocyte count and serum lysozyme
Haematological studies distributions.
The mean peripheral blood white cell count was of 18 months from diagnosis (Figure 2). When age was
20.7 x 109 P1 (range 2.5-178.0 x 109 01) and the mean PB taken into account (two groups <75 yrs and >75yrs; in two
monocyte count 4.4 x 109 P' (range 1.0-45.0 x 109Pi). The cases the date of birth was unknown giving a total of 77 majority of cases had low monocyte counts (Figure 1) with
e _
only 17(17.5%) cases having a count exceeding 5.0 0.1- evaluable patients), it was found that the older age group did
A similar distribution curve was seen for PB white count. worse (Figure 3) although this difference was of borderline
Serum lysozyme was estimated in 59 cases with an observed significance (P=0.057).
range (Figure 1) of 170-15,600uml-1 (mean 2,707uml-1). Total peripheral blood white cell counts (<10.0 versus
Fe . 170-15,600suzm lt (menan mang. 10.0 x 109 1 or greater) were not significant as a prognostic
Five asshd sm lyozyme
within the normal rne. factor (P=0.165) even though there was a trend for the low Bone marrow monocytes ranged from 0.5%-74%/ (mean cong
12.5%) and BM double esterase positive cells from 0-24% count group to survive longer. Peripheral blood monocyte 12.5%) an BM dobl estrs psitv cels from 0*4 count (<5.0 versus 5.0 x 109 1-or over) was however
with a mean of 4.8%. BM blasts were <10% in all cases.
Statistical relationships for the data were assessed using significant (P=0.013) as a prognostic factor (Figure 4) with
Spearmans non-parametric rank correlation coefficient the high count group having a median survival from
(Table,1). AbsolutePB monocyte countsshowed significant diagnosis of 14 months and the low count group a median (TableaI..
A ote PB C counts . _
seu survival of 2 years. Although all patients were known to
ysozyme concentrations (P=0.005)buts unexpectedly there have a monocyte count of >1 x 109 -1, in 7 cases the .yszym cocnrain (P=.0.05 but unxetdy there. absolute number had not been documented and these were
was no statistical relationship between PB monocyte counts
and the proportions of BM monocytes (P=0.5). The excluded from this part of the analysis.
proportions of DE-positive cells were however correlated DE positive cells in bone marrow were not a significant s of D e cs were h r d prognostic factor (P=0.724) and neither was the percentage with BM monocyte percentages (P<0.0l), but not with any of no ctes (P=0.964)a
of the other features examined. v B
Serum lysozyme was divided into two groups (<2,500 and
Survival data >2,500uml- 1); a cut-off point selected arbitrarily as five times the normal upper limit, the low lysozyme group
Survival was calculated using the Kaplan-Meier method to surviving longer than those with levels exceeding
cancer death and this gave a median survival for all patients 2,500uml-' (P=0.028; Figure 5).
Table I Spearman correlation coefficients for relationships between various parameters in chronic myelomonocytic
leukaemia (CMML)
Total WBC PB monocytes BM monocytes BM DE +vye Serum lysozyme
Total WBC(x1091-') -P<0.OOla NSb NS P=0.002
PBmonocytes(xl091-) P<0.001 -NS NS P=0.003
BM monocytes (%) NS NS -P=0.007 NS
BMDE+vecells(%) NS NS P=0.007 -NS
Serum lysozyme (umK 1) P=0.002 P=0.003 NS NS-
aResults expressed as P values for any given Spearman coefficient value; bNS =not significant.PROGNOSIS AND SURVIVAL IN CMML 61
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Figure 2 Survival in CMML - Allcases (n=79).
Multiple regression analysis
100 Cox's proportional hazards regression model was used to
investigate the prognostic importance of the variables in a
continuous format (Table ot). With various combinations,
80 only serum lysozyme was consistently selected by the
automatic stepwise selection procedure. In discrete format,
c: % serum lysozyme was again consistently selected, but PB
60 monocytes and age also appeared to provide additional
60 t
cprognostic information. It was concluded from this analysis
Lessthan 75(33) Inthat serum lysozyme was the most important prognostic
C lI eeaalbew on 0 ae fcrioa( kn
40 factor of those examined, both in continuous and discrete
-I hformat. Blood monocytes and age also affected prognosis
L-- - - - - - - - - - but were more noticeable in their effect when grouped into
* 20 -. Idiscrete variables.
P=0.0575 175 or more (44)
2I I Table 4a Cox's model analysis for variables in continuous format
0 1 2 3 4 5b_ _ _ _ _ _ _ _ _ _ _ _ _ _
Time (years) Variables selected
VariaLews inve.stigate (Pe valYer'tehiue) (o
Figure3 Survival in CMML by age group (n= (77).
Serum lysozyme, PB monocytes Serum lysozyme (P =0.002)
Serum lysozyme, age Serum lysozyme (P=0.003)
100 iPB monocytes, age Neither entered
Serum lysozyme, age,
PB monocytes Serum lysozyme (P =0.002)
80 -L
60
- Second malignancies
Less than 5 (56) In the 79 patients where accurate survival and follow-up
P= 0.076 respectiel were available we found 10 cases of carcinoma (2 skin, 2
colonic, 1 breast, 1 ovarian, 1 prostate, 1 bladder andI
younger patients, bohfo Bmooyes(=.09,an Muterus) with one patient having metastatic brain deposits
20 w with unknown primary. In addition two CMML patients
I ~~~~~~~had myeloma and one had symptomless paraproteinaemia
with a monoclonal increase in BM plasma cells (15%). In
P=0.0135 5 r more (16)both myeloma patients, CMML and myeloma were
0 2 3 4 5 diagnosed simultaneously but in the carcinoma group 7/10
Time (years) were diagnosed as having carcinoma before the diagnosis of
CMML was made. Using the 'Man Years' technique (for
Fp'igure 4 Suirvival in C-MML by bloodi monnoyte couint (n 72) oprn bevdwt xece niecso iessi62 A.N. STARK et al.
maintained for 14 months before relapsing. None of the a poor indicator of monocytic load in CMML, as is the
patients with AML were considered as having true second bone marrow blast cell count in other types of leukaemia,
malignancies since it is likely that in these cases the AML and that serum lysozyme more accurately reflects total body
develops from the same clone as the CMML, and can monocytic tumour load and turnover analagous to LDH
reasonably be regarded as a progression of the original enzymes in malignancies (haemopoietic and non-
disease. haemopoietic) generally (Ho et al., 1982; Stefani, 1985; Scott
et al., 1986). Five cases had a normal serum lysozyme but
Discussion fulfilled the FAB criteria for the diagnosis of CMML in
every other way, and 4 of these had > 10% BM monocytes.
CMML is a relatively uncommon disease predominantly of The occurrence of a normal serum lysozyme in occasional
the elderly for which, in the majority of cases, aggressive patients with CMML is therefore unusual, but not without
therapeutic regimens are inappropriate. However, if it were precedence as cases of well differentiated acute monocytic
possibl to identify patients who hadapoorprognis t, leukaemia (M5b) may also have a normal serum lysozyme possible to identify patients who had a poor prognosis then, Nroke l,18) apart from the obvious benefits of having prognostic (Norfolk etdat., 1985).
information available on any given patient, treatment might The median survival in our study (18 months) was similar bfmorerationalal p anned. to two earlier studies (Solal-Celigny et al., 1984; beWmoehravetshownallyplanned. CMML atietswthAlessandrino et al., 1985; median survivals 15.8 and 18 We have shown that CMML patients with a high months respectively), although less than that reported
monocyte counts but this did not appear to be related to recently (Groupe Francais de Cytogenetique Hematologique,
monocytic tumour load, as reflected by monocytic 1986; median survival 27 months), confirming that the
infiltration of bone marrow. In contrast to a recent study disease has a poor prognosis with few patients surviving
(Groupe Francais de Cytogenetique, 1986), which reported more than two years following clinical presentation.
59 cases of high count (d>5.0 x 10- 19)CMML in a total of It has also been suggested that the incidence of second
120 (49.2%) patients, we found only a small number (17/97: malignancies in CMML may be increased (Copplestone et
17 .5%) Reasons for this discrepancy are unclear but may be al., 1986; Mufti et al., 1983) and some authors consider that
related to sampling methods and diagnostic criteria a picture of CMML may occur as part of a paraneoplastic
employed. In our survey, all cases with primary dysplasia syndrome (Haznedar, 1985; Raz et al., 1984; Sans-Sabrafen
referred from a wide population area were examined as et al., 1986). Seven of our series of patients had a carcinoma
potential 'low count' CMML and, conversely, we reviewed present before the diagnosis of CMML was made and it is
all cases of atypical chronic granulocytic leukaemia (CGL) therefore possible that in these cases the picture of dysplasia
and myeloproliferative disease as potential 'high count' cases and monocytosis was a result of the carcinoma, rather than
and cases were diagnosed as CMML only if they fulfilled the representing the development of a new tumour. However,
FAB criteria for this diagnosis. It is also accepted that it can when the 10 cases of carcinoma and 2 of myeloma were
be difficult to differentiate between phl negative CGL and analyzed against an age and sex matched group, no
CMML. statistical increase of second malignancy was found.
Increased BM monocytic components were found in many It can be argued that since paraprotein was not sought
of our cases (mean 12.5%BM monocytes), in contrast to routinely in all cases it is possible that the true incidence
early morphological descriptions (Broun, 1969; Miescher & of myeloma was underestimated. While this may be true,
Farquet, 1974), but were not significantly correlated with increased plasma cells were only found in one bone marrow
absolute PB monocyte counts. An increase in BM monocytes (apart from those with myeloma) and none of the other
was however associated with the presence of abnormal patients had any of the clinical or biochemical features of
numbers of double esterase (DE)-positive cells. It has been the disease. Paraprotein in CMML has been found in the
shown previously that DE +ve cells in the BM in MDS are absence of increased BM plasma cells (Barnard et al., 1979)
probably of granulocytic origin (Scott et al., 1984) so the but this is presumably uncommon as all 12 patients with
association of DE +ve cells and BM monocytes cannot be paraproteinaemia in a recent study (Group Francais de
explained on the basis that the same cells are being stained. Cytogenetique Hematologique, 1986) showed some increase
Rather it would appear that the increased monocytic in BM plasma cells. It has been proposed in another study
involvement of BM is associated with the abnormality (Copplestone et al., 1986) that the occurrence of B-cell
(possibly due to gene derepression) in enzyme expression that malignancy in MDS does not represent a true second tumour
causes granulocyte precursors to express monocyte- and may be part of the same clonal disturbance, though we
associated ANA in addition to chloroacetate esterase found no direct evidence for this in our study.
As in leukaemia generally, age significantly influenced In conclusion, we have analysed 97 cases of CMML for
prognosis, indepe enetly of the other factors examined prognostic factors and found that age, PB monocyte count
However, it is difficult to say whether this means the disease and serum lysozyme levels are significant single independent
is inherently more aggressive in an older population or prognostic factors. Multiple regression analysis showed
whether, as might be expected, older people simply have a serum lysozyme to be the most important of these although
higher overall mortality with the CMML contributing in a the other factors remained significant even when lysozyme
non-specific way. was taken into account. Use of these easily available features
Serum lysozyme was the single most valuable prognostic should allow better prediction of survival in CMML
factor whether taken as a discrete or continuous variable.
Serum lysozyme is elevated in many types of myeloid
leukaemias, particularly of monocytic type (Milligan et at.,
1984; Norfolk et at., 1985; Scott et at., 1985), and shows We thank Drs A. Antonis, I.C. Balfour, D.L. Barnard, J.A. Child,
some correlation with serum beta-2 microglobulin levels in A.T. Edwards, M.S. Edwards, M.C. Galvin, K. Hunt, M.M.
monocytic proliferations (Norfolk et at., 1985). The McEvoy, S. Mayne, R.D. Pyrah, L.A. Parapia, R. Sibbald and J.G.
concentrations of these serum components are considered to Tetley for allowing us to study their patients.
reflect the degree of monocytic infiltration, and hence We especially thank the Yorkshire Regional Cancer Registry for
tumour load in CMML, and this supports our observation providing much of the data and Dr R.A. Cartwright and staff of the
that erumIysoyme i a srongprognsticindiator Yorkshire Regional Cancer Organisation (Epidemiology) for their tha seu lyoyei togprgotcidctr help in interpretation of data.
However, it iS of interest thnat serum lysozyme was not Work in this Department is supported by the LRF and the
related to BM monocyte count, which also might be thought Friends of the Leukaemia Unit, Leeds General Infirmary, and many
to provide evidence of monocytic tumour mass. One possible of the cases examined were submitted as part of the LRF Data
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